Kathryn H. Gunn, Benjamin S. Roberts, Fengbin Wang, Joshua D. Strauss, Mario J. Borgnia, Edward H. Egelman, Saskia B. Neher Proceedings of the National Academy of ...
Study deciphers the molecular handshake between LDL receptors and apoB100, shedding light on cholesterol metabolism and its role in cardiovascular disease. Study: Structure of apolipoprotein B100 ...
Scientists have made a significant breakthrough in understanding how 'bad' cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body. The researchers were able to show ...
Despite decades of study, a pharmacopoeia of medicines, and untold millions in pharmaceutical research, heart disease remains the leading cause of death around the world. Excess cholesterol in ...
Lipoprotein(a) is a presumed risk factor for atherosclerotic cardiovascular disease. Olpasiran is a small interfering RNA that reduces lipoprotein(a) synthesis in the liver. We conducted a randomized, ...
The U.S. government’s premier research body has made an important discovery that could help create new drugs to lower “bad” cholesterol, and hopefully prevent heart attacks and stroke. But the ...
National Institute of Health (NIH) scientists have made a significant breakthrough in understanding how "bad" cholesterol, known as low-density lipoprotein-cholesterol or LDL-C, builds up in the body.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback